CN100506235C - 一种治疗脑血管疾病的冻干制剂 - Google Patents
一种治疗脑血管疾病的冻干制剂 Download PDFInfo
- Publication number
- CN100506235C CN100506235C CNB2006100512325A CN200610051232A CN100506235C CN 100506235 C CN100506235 C CN 100506235C CN B2006100512325 A CNB2006100512325 A CN B2006100512325A CN 200610051232 A CN200610051232 A CN 200610051232A CN 100506235 C CN100506235 C CN 100506235C
- Authority
- CN
- China
- Prior art keywords
- solution
- freeze
- ginsenoside
- excipient
- temperature
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 238000002360 preparation method Methods 0.000 title claims description 16
- 208000019553 vascular disease Diseases 0.000 title abstract 2
- 230000002490 cerebral effect Effects 0.000 title description 8
- 239000000546 pharmaceutical excipient Substances 0.000 claims abstract description 33
- 239000000203 mixture Substances 0.000 claims description 41
- FBFMBWCLBGQEBU-RXMALORBSA-N (2s,3r,4s,5s,6r)-2-[(2r,3r,4s,5s,6r)-2-[[(3s,5r,6s,8r,9r,10r,12r,13r,14r,17s)-3,12-dihydroxy-4,4,8,10,14-pentamethyl-17-[(2s)-6-methyl-2-[(2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyhept-5-en-2-yl]-2,3,5,6,7,9,11,12,13,15,16,17-dodecah Chemical compound O([C@@](C)(CCC=C(C)C)[C@@H]1[C@@H]2[C@@]([C@@]3(C[C@@H]([C@H]4C(C)(C)[C@@H](O)CC[C@]4(C)[C@H]3C[C@H]2O)O[C@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)O[C@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)O)C)(C)CC1)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O FBFMBWCLBGQEBU-RXMALORBSA-N 0.000 claims description 40
- FBFMBWCLBGQEBU-GYMUUCMZSA-N 20-gluco-ginsenoside-Rf Natural products O([C@](CC/C=C(\C)/C)(C)[C@@H]1[C@H]2[C@H](O)C[C@H]3[C@](C)([C@]2(C)CC1)C[C@H](O[C@@H]1[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O2)[C@@H](O)[C@H](O)[C@@H](CO)O1)[C@H]1C(C)(C)[C@@H](O)CC[C@]31C)[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 FBFMBWCLBGQEBU-GYMUUCMZSA-N 0.000 claims description 40
- HYPFYJBWSTXDAS-UHFFFAOYSA-N Ginsenoside Rd Natural products CC(=CCCC(C)(OC1OC(CO)C(O)C(O)C1O)C2CCC3(C)C4CCC5C(C)(C)C(CCC5(C)C4CC(O)C23C)OC6OC(CO)C(O)C(O)C6OC7OC(CO)C(O)C(O)C7O)C HYPFYJBWSTXDAS-UHFFFAOYSA-N 0.000 claims description 40
- UOJAEODBOCLNBU-UHFFFAOYSA-N vinaginsenoside R4 Natural products C1CC(C2(CC(O)C3C(C)(C)C(OC4C(C(O)C(O)C(CO)O4)OC4C(C(O)C(O)C(CO)O4)O)CCC3(C)C2CC2O)C)(C)C2C1C(C)(CCC=C(C)C)OC1OC(CO)C(O)C(O)C1O UOJAEODBOCLNBU-UHFFFAOYSA-N 0.000 claims description 40
- 238000009472 formulation Methods 0.000 claims description 35
- 238000004108 freeze drying Methods 0.000 claims description 30
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims description 25
- 208000026106 cerebrovascular disease Diseases 0.000 claims description 22
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 15
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims description 12
- 229930195725 Mannitol Natural products 0.000 claims description 12
- 239000000594 mannitol Substances 0.000 claims description 12
- 235000010355 mannitol Nutrition 0.000 claims description 12
- ZGTMUACCHSMWAC-UHFFFAOYSA-L EDTA disodium salt (anhydrous) Chemical compound [Na+].[Na+].OC(=O)CN(CC([O-])=O)CCN(CC(O)=O)CC([O-])=O ZGTMUACCHSMWAC-UHFFFAOYSA-L 0.000 claims description 11
- 229920002307 Dextran Polymers 0.000 claims description 10
- 238000001035 drying Methods 0.000 claims description 10
- 238000007710 freezing Methods 0.000 claims description 10
- 230000008014 freezing Effects 0.000 claims description 10
- 238000000859 sublimation Methods 0.000 claims description 10
- 230000008022 sublimation Effects 0.000 claims description 10
- 229910052799 carbon Inorganic materials 0.000 claims description 9
- 238000001914 filtration Methods 0.000 claims description 8
- 238000000034 method Methods 0.000 claims description 8
- 238000010438 heat treatment Methods 0.000 claims description 6
- 239000002510 pyrogen Substances 0.000 claims description 6
- FZWBNHMXJMCXLU-BLAUPYHCSA-N isomaltotriose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@@H](OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O)O1 FZWBNHMXJMCXLU-BLAUPYHCSA-N 0.000 claims description 5
- 239000002904 solvent Substances 0.000 claims description 5
- 238000003756 stirring Methods 0.000 claims description 5
- 238000005262 decarbonization Methods 0.000 claims description 3
- 239000012535 impurity Substances 0.000 claims description 2
- 239000003960 organic solvent Substances 0.000 claims description 2
- 230000001954 sterilising effect Effects 0.000 claims description 2
- 238000004659 sterilization and disinfection Methods 0.000 claims description 2
- 239000003814 drug Substances 0.000 abstract description 27
- 229940079593 drug Drugs 0.000 abstract description 12
- 239000000463 material Substances 0.000 abstract description 6
- 229940089161 ginsenoside Drugs 0.000 abstract 1
- 229930182494 ginsenoside Natural products 0.000 abstract 1
- 239000000243 solution Substances 0.000 description 48
- 238000002347 injection Methods 0.000 description 24
- 239000007924 injection Substances 0.000 description 24
- 239000008280 blood Substances 0.000 description 22
- 210000004369 blood Anatomy 0.000 description 21
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 12
- 230000017531 blood circulation Effects 0.000 description 12
- 210000000269 carotid artery external Anatomy 0.000 description 11
- 208000005189 Embolism Diseases 0.000 description 8
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 8
- 208000001435 Thromboembolism Diseases 0.000 description 8
- 206010008118 cerebral infarction Diseases 0.000 description 8
- UIAGMCDKSXEBJQ-IBGZPJMESA-N 3-o-(2-methoxyethyl) 5-o-propan-2-yl (4s)-2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate Chemical compound COCCOC(=O)C1=C(C)NC(C)=C(C(=O)OC(C)C)[C@H]1C1=CC=CC([N+]([O-])=O)=C1 UIAGMCDKSXEBJQ-IBGZPJMESA-N 0.000 description 7
- 206010028851 Necrosis Diseases 0.000 description 7
- 239000004677 Nylon Substances 0.000 description 7
- 238000002474 experimental method Methods 0.000 description 7
- 230000017074 necrotic cell death Effects 0.000 description 7
- 229960000715 nimodipine Drugs 0.000 description 7
- 229920001778 nylon Polymers 0.000 description 7
- 239000000047 product Substances 0.000 description 7
- 239000011780 sodium chloride Substances 0.000 description 7
- 206010008190 Cerebrovascular accident Diseases 0.000 description 6
- 241000180649 Panax notoginseng Species 0.000 description 6
- 235000003143 Panax notoginseng Nutrition 0.000 description 6
- 208000006011 Stroke Diseases 0.000 description 6
- 150000001875 compounds Chemical class 0.000 description 6
- 230000000694 effects Effects 0.000 description 6
- 239000012528 membrane Substances 0.000 description 6
- 229930182490 saponin Natural products 0.000 description 6
- 150000007949 saponins Chemical class 0.000 description 6
- 235000017709 saponins Nutrition 0.000 description 6
- 210000004556 brain Anatomy 0.000 description 5
- 230000001737 promoting effect Effects 0.000 description 5
- 230000001105 regulatory effect Effects 0.000 description 5
- 238000012216 screening Methods 0.000 description 5
- 230000001225 therapeutic effect Effects 0.000 description 5
- 201000006474 Brain Ischemia Diseases 0.000 description 4
- 206010008120 Cerebral ischaemia Diseases 0.000 description 4
- 206010061216 Infarction Diseases 0.000 description 4
- 239000003795 chemical substances by application Substances 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 239000000839 emulsion Substances 0.000 description 4
- 230000007574 infarction Effects 0.000 description 4
- 238000010253 intravenous injection Methods 0.000 description 4
- 208000011580 syndromic disease Diseases 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- JGSARLDLIJGVTE-UHFFFAOYSA-N 3,3-dimethyl-7-oxo-6-[(2-phenylacetyl)amino]-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid Chemical compound O=C1N2C(C(O)=O)C(C)(C)SC2C1NC(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-UHFFFAOYSA-N 0.000 description 3
- 206010008111 Cerebral haemorrhage Diseases 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- 244000131316 Panax pseudoginseng Species 0.000 description 3
- 210000004004 carotid artery internal Anatomy 0.000 description 3
- 230000006378 damage Effects 0.000 description 3
- 230000007850 degeneration Effects 0.000 description 3
- 239000000945 filler Substances 0.000 description 3
- 239000000706 filtrate Substances 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 230000010412 perfusion Effects 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 239000001397 quillaja saponaria molina bark Substances 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 230000002792 vascular Effects 0.000 description 3
- 239000008215 water for injection Substances 0.000 description 3
- 206010008132 Cerebral thrombosis Diseases 0.000 description 2
- 101710088194 Dehydrogenase Proteins 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- 240000006509 Gynostemma pentaphyllum Species 0.000 description 2
- 235000002956 Gynostemma pentaphyllum Nutrition 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- 206010062717 Increased upper airway secretion Diseases 0.000 description 2
- 201000001429 Intracranial Thrombosis Diseases 0.000 description 2
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 description 2
- 235000003140 Panax quinquefolius Nutrition 0.000 description 2
- 241000700159 Rattus Species 0.000 description 2
- 206010063837 Reperfusion injury Diseases 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 239000003513 alkali Substances 0.000 description 2
- 210000001367 artery Anatomy 0.000 description 2
- 230000000903 blocking effect Effects 0.000 description 2
- 210000005013 brain tissue Anatomy 0.000 description 2
- 239000007853 buffer solution Substances 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 239000003610 charcoal Substances 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 230000006735 deficit Effects 0.000 description 2
- 231100000673 dose–response relationship Toxicity 0.000 description 2
- 235000008434 ginseng Nutrition 0.000 description 2
- 238000009499 grossing Methods 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 208000028867 ischemia Diseases 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 210000003657 middle cerebral artery Anatomy 0.000 description 2
- 239000000178 monomer Substances 0.000 description 2
- 231100000915 pathological change Toxicity 0.000 description 2
- 230000036285 pathological change Effects 0.000 description 2
- 208000026435 phlegm Diseases 0.000 description 2
- 238000001556 precipitation Methods 0.000 description 2
- PKDBCJSWQUOKDO-UHFFFAOYSA-M 2,3,5-triphenyltetrazolium chloride Chemical compound [Cl-].C1=CC=CC=C1C(N=[N+]1C=2C=CC=CC=2)=NN1C1=CC=CC=C1 PKDBCJSWQUOKDO-UHFFFAOYSA-M 0.000 description 1
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 206010003694 Atrophy Diseases 0.000 description 1
- 206010008088 Cerebral artery embolism Diseases 0.000 description 1
- JOYRKODLDBILNP-UHFFFAOYSA-N Ethyl urethane Chemical compound CCOC(N)=O JOYRKODLDBILNP-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 206010019468 Hemiplegia Diseases 0.000 description 1
- 208000032843 Hemorrhage Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 241001597008 Nomeidae Species 0.000 description 1
- 235000003181 Panax pseudoginseng Nutrition 0.000 description 1
- 208000031971 Yin Deficiency Diseases 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 229940035676 analgesics Drugs 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 239000000730 antalgic agent Substances 0.000 description 1
- 210000002551 anterior cerebral artery Anatomy 0.000 description 1
- 210000000436 anus Anatomy 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 230000037444 atrophy Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 230000036760 body temperature Effects 0.000 description 1
- 210000000133 brain stem Anatomy 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 230000001914 calming effect Effects 0.000 description 1
- 210000001168 carotid artery common Anatomy 0.000 description 1
- 210000001638 cerebellum Anatomy 0.000 description 1
- 230000004087 circulation Effects 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 229940041984 dextran 1 Drugs 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 238000004043 dyeing Methods 0.000 description 1
- 230000005611 electricity Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 230000001815 facial effect Effects 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 230000002440 hepatic effect Effects 0.000 description 1
- 238000010191 image analysis Methods 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 201000010849 intracranial embolism Diseases 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 239000012567 medical material Substances 0.000 description 1
- 230000004089 microcirculation Effects 0.000 description 1
- 238000000465 moulding Methods 0.000 description 1
- 230000001338 necrotic effect Effects 0.000 description 1
- 210000000956 olfactory bulb Anatomy 0.000 description 1
- 229940063517 omeprazole sodium Drugs 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 210000003800 pharynx Anatomy 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- KNVABRFVZVESIL-UHFFFAOYSA-N sodium;6-methoxy-2-[(4-methoxy-3,5-dimethylpyridin-2-yl)methylsulfinyl]-1h-benzimidazole Chemical compound [Na+].N=1C2=CC(OC)=CC=C2NC=1S(=O)CC1=NC=C(C)C(OC)=C1C KNVABRFVZVESIL-UHFFFAOYSA-N 0.000 description 1
- 238000001694 spray drying Methods 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 210000001685 thyroid gland Anatomy 0.000 description 1
- 210000001835 viscera Anatomy 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
Description
Claims (3)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CNB2006100512325A CN100506235C (zh) | 2006-09-26 | 2006-09-26 | 一种治疗脑血管疾病的冻干制剂 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CNB2006100512325A CN100506235C (zh) | 2006-09-26 | 2006-09-26 | 一种治疗脑血管疾病的冻干制剂 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN1943583A CN1943583A (zh) | 2007-04-11 |
CN100506235C true CN100506235C (zh) | 2009-07-01 |
Family
ID=38043377
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CNB2006100512325A Expired - Fee Related CN100506235C (zh) | 2006-09-26 | 2006-09-26 | 一种治疗脑血管疾病的冻干制剂 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN100506235C (zh) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN110025623A (zh) * | 2019-03-21 | 2019-07-19 | 李和伟 | 一种冻干制剂及其制备方法和应用 |
-
2006
- 2006-09-26 CN CNB2006100512325A patent/CN100506235C/zh not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
CN1943583A (zh) | 2007-04-11 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP3505161B1 (en) | Sublingual pharmaceutical composition of edaravone and (+)-2-borneol | |
CN100363022C (zh) | 一种具有免疫调节作用的药物组合物及其制备方法 | |
US6455077B2 (en) | Herbal composition and method of manufacturing such composition for the management of gynecological disorders | |
WO2013189285A1 (zh) | 曲札茋苷在制备改善微循环障碍药物中的应用 | |
CN104706704B (zh) | 玛咖组合物、其复方制剂及其应用 | |
CN101780227B (zh) | 一种治疗中风急性期的中药组合物及其制备方法 | |
CN100506235C (zh) | 一种治疗脑血管疾病的冻干制剂 | |
CN110025664B (zh) | 用于防治脑梗死和/或血管性痴呆的药物组合物及其应用 | |
CN114869928B (zh) | 用于治疗脑血管疾病的中药组合物及其用途 | |
CN102861230A (zh) | 一种中药组合物在制备治疗脏器纤维化的药物中的应用 | |
CN105878470B (zh) | 一种清开灵药物组合物 | |
WO2009135423A1 (zh) | 治疗心脑血管疾病的药物组合物及其制备方法和药盒 | |
CN102048824B (zh) | 一种用于治疗脑血管疾病的中药组合物及其应用 | |
CN111920835A (zh) | 一种药物制剂在制备治疗老年痴呆的药物中的应用 | |
CN111346089A (zh) | 一种药物制剂及其制备方法 | |
CN102526195B (zh) | 治疗冠心病的药物组合物及其制备方法 | |
CN102716231B (zh) | 一种治疗脑损伤和脑水肿的中药组合物及其应用 | |
US20230043437A1 (en) | Compound preparation for neuranagenesis, and preparation method therefor and use thereof | |
CN113827587A (zh) | 丹酚酸a在制备预防血栓性脑缺血的药物中的应用 | |
CN108671074A (zh) | 预防和/或治疗心脑血管疾病的银杏叶枸杞复方口服液及其制备方法 | |
CN101167733A (zh) | 一种用于预防和治疗缺血性脑中风的静脉注射用粉针及其制备方法 | |
CN110478384B (zh) | 防风总香豆素的提取方法及其在制备增强中枢神经系统药物药效的组合物中的应用 | |
CN107865875A (zh) | 一种含有七叶皂苷a的药物组合物 | |
CN101780224B (zh) | 包含旋复花的组合物的用途 | |
CN102178751B (zh) | 一种清脑止痛制剂 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
DD01 | Delivery of document by public notice |
Addressee: Qian Youbin Document name: Notice of termination |
|
DD01 | Delivery of document by public notice |
Addressee: Qian Youbin Document name: Notification of Termination of Procedure |
|
TR01 | Transfer of patent right |
Effective date of registration: 20181214 Address after: 550018 6th Floor, Kekaiyuan, Koujie Road Estuary, Wudang District, Guiyang City, Guizhou Province Patentee after: Xinbang Pharmacy Co., Ltd., Guizhou Address before: 550014 Xinbang Avenue 227, Baiyun Economic Development Zone, Guiyang City, Guizhou Province Patentee before: Xinbang Yuandong Pharmaceutical Co., Ltd., Guizhou |
|
TR01 | Transfer of patent right | ||
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20090701 Termination date: 20190926 |
|
CF01 | Termination of patent right due to non-payment of annual fee |